Guidance being developed ... there has been outreach. BIMO Ch 5.10 - FDA can request read-only access. It is a goal to like see some sort of direct access similar to EMA, but FDA is not there yet. Need to harmonize internally first. #sqa2022
FDA: Success metrics are internal to BIMO. The goal is to get on the same page and move forward. New internal compliance function is relevant. The goal is consistency between divisions. #sqa2022
When we inspect sponsor, it is application driven and will trigger an inspection - not based on studies. We would review the compliance program at minimum. Unrelated to GLP studies. #sqa2022
In the UK, they will perform system and study-specific inspections.
FDA -- What may be different is the logistical challenges, translation issue. But inspection approach is the same as what they do domestically. #sqa2022
FDA encourages this approach - great process validation guidance document exists. It from design verification to 2nd stage (Process performance Qualification). It must be continuously verified once it is in the market - the stage 3 concept. #sqa2022
Starting in ~10 minutes: (Q-3) Beyond Audits and Inspections – Enhancing the Role of Quality in #Pharmacovigilance. Sessions will continue today through 5 PM PDT.